Zisper LS Tablet contains Risperidone 2 mg and Trihexyphenidyl 2 mg, formulated for the management of psychiatric disorders requiring antipsychotic and antiparkinsonian therapy. Risperidone, a benzisoxazole derivative, acts as a dopamine D2 and serotonin 5-HT2 receptor antagonist, effectively reducing symptoms of schizophrenia, bipolar disorder, and irritability associated with autism. Trihexyphenidyl, an anticholinergic agent, is included to mitigate extrapyramidal side effects such as dystonia, parkinsonism, and akathisia commonly induced by antipsychotic treatment. Zisper LS is indicated for patients who require both antipsychotic efficacy and control of movement disorders secondary to dopamine blockade. The combination enhances patient compliance by reducing pill burden and improving tolerability. Dosage should be individualized based on clinical response and tolerability, with careful monitoring for adverse effects including sedation, orthostatic hypotension, anticholinergic effects, and metabolic changes. Caution is advised in patients with cardiovascular disease, seizure disorders, or a history of neuroleptic malignant syndrome. Regular assessment of therapeutic outcomes and side effects is essential to optimize treatment. Zisper LS should be used under strict medical supervision, ensuring appropriate titration and adherence to recommended guidelines.